Contribution of B-1a cells to systemic lupus erythematosus in the NZM2410 mouse model

Annals of the New York Academy of Sciences

Volumn 1362, Issue 1, 2015, Pages 215-223

  Xu, Zhiwei ^a   Morel, Laurence ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

B 1a cell; NZM2410 mice; Systemic lupus erythematosus

Indexed keywords

AUTOANTIBODY; CD4 ANTIGEN; INTERLEUKIN 10; PROTEIN P18; CDKN2C PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 2C;

ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; B 1A CELL; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CDKN2C GENE; CELL CYCLE PROGRESSION; CELL EXPANSION; EFFECTOR CELL; GENE; HUMAN; IMMUNOSTIMULATION; INFLAMMATION; MOUSE; MOUSE MODEL; NONHUMAN; NZM2410 MOUSE; PATHOGENESIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; ANIMAL; DEFICIENCY; DISEASE MODEL; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ANIMALS; B-LYMPHOCYTE SUBSETS; CYCLIN-DEPENDENT KINASE INHIBITOR P18; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE;

EID: 84959455830     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12607     Document Type: Article

References (72)

1. Sang, A. et al. 2012. Animal models of molecular pathology: systemic Lupus Erythematosus. In Progress in Molecular Biology and Translational Science. Vol. 105. P.M. Conn, Ed.: 321-370. Academic Press.
2. Theofilopoulos, A.N. & F.J. Dixon. 1985. Murine models of systemic lupus erythematosus. Adv. Immunol. 37: 269-390.
3. Wakeland, E.K. et al. 2001. Delineating the genetic basis of systemic lupus erythematosus. Immunity 15: 397-408.
4. Harley, I.T. et al. 2009. Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat. Rev. Genet. 10: 285-290.
5. Morel, L. 2010. Genetics of SLE: evidence from mouse models. Nat. Rev. Rheumatol. 6: 348-357.
6. Vaughn, S.E. et al. 2012. Genetic susceptibility to lupus: the biological basis of genetic risk found in B cell signaling pathways. J. Leukoc. Biol. 92: 577-591.
7. Morel, L. et al. 1994. Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1: 219-229.
8. Morel, L. 2012. Mapping lupus susceptibility genes in the NZM2410 mouse model. Adv. Immunol. 115: 113-139.
9. Morel, L. et al. 2000. Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. Proc. Natl. Acad. Sci. USA 97: 6670-6675.
10. Lipsky, P.E. 2001. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol. 2: 764-766.
11. Xiong, W. & R.G. Lahita. 2014. Pragmatic approaches to therapy for systemic lupus erythematosus. Nat. Rev. Rheumatol. 10: 97-107.
12. Kamal, A. The efficacy of novel B cell biologics as the future of SLE treatment: A review. Autoimm. Rev. pii: S1568-9972(14)00164-5. doi: 10.1016/j.autrev.2014.08.020. [Epub ahead of print]
13. MacGregor, J.S. 2014. Lilly to discontinue development of Tabalumab based on efficacy results in phase 3 Lupus studies. In FierceBiotech.
14. Casola, S. 2007. Control of peripheral B-cell development. Curr. Opin. Immunol. 19: 143-149.
15. Duan, B. & L. Morel. 2006. Role of B-1a cells in autoimmunity. Autoimmun. Rev. 5: 403-408.
16. Berland, R. & H.H. Wortis. 2002. Origins and functions of B-1 cells with notes on the role of CD5. Ann Rev. Immunol. 20: 253-300.
17. Enghard, P. et al. 2010. Class switching and consecutive loss of dsDNA reactive B1a B cells from the peritoneal cavity during murine lupus development. Eur. J. Immunol. 40: 1809-1818.
18. Ito, T. et al. 2004. Defective B1 cell homing to the peritoneal cavity and preferential recruitment of B1 cells in the target organs in a murine model for systemic lupus erythematosus. J. Immunol. 172: 3628-3634.
19. Moreth, K. et al. 2010. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J. Clin. Invest. 120: 4251-4272.
20. Tumang, J.R. et al. 2005. Spontaneously Ig-secreting B-1 cells violate the accepted paradigm for expression of differentiation-associated transcription factors. J. Immunol. 174: 3173-3177.
21. O'Garra, A. & M. Howard. 1992. IL-10 production by CD5 B cells. Ann. N. Y. Acad. Sci. 651: 182-199.
22. Ishida, H. et al. 1994. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J. Exp. Med. 179: 305-310.
23. Yin, Z. et al. 2002. IL-10 regulates murine lupus. J. Immunol. 169: 2148-2155.
24. Gunnarsson, I. et al. 2000. Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA. Rheumatology (Oxford). 39: 886-893.
25. Tyrrell-Price, J., P.M. Lydyard & D.A. Isenberg. 2001. The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus. Clin. Exp. Immunol. 124: 118-125.
26. Candando, K.M., J.M. Lykken & T.F. Tedder. 2014. B10 cell regulation of health and disease. Immunol. Rev. 259: 259-272.
27. Mohan, C. et al. 1998. Accumulation of splenic B1a cells with potent antigen-presenting capability in NZM2410 lupus-prone mice. Arthritis Rheum. 41: 1652-1662.
28. Sato, T. et al. 2004. Aberrant B1 cell migration into the thymus results in activation of CD4 T cells through its potent antigen-presenting activity in the development of murine lupus. Eur. J. Immunol. 34: 3346-3358.
29. Zhong, X. et al. 2007. Reciprocal generation of Th1/Th17 and T(reg) cells by B1 and B2 B cells. Eur. J. Immunol. 37: 2400-2404.
30. Zhong, X. et al. 2009. A novel subpopulation of B-1 cells is enriched with autoreactivity in normal and lupus-prone mice. Arthritis Rheum. 60: 3734-3743.
31. Yang, Z. et al. 2011. Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clin. Exp. Med. 11: 75-80.
32. Wang, Y. & T.L. Rothstein. 2012. Induction of Th17 cell differentiation by B-1 cells. Front. Immunol. 3: 281.
33. Hsu, H.C. et al. 2008. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat. Immunol. 9: 166-175.
34. Doreau, A. et al. 2009. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat. Immunol. 10: 778-785.
35. Zhang, Z., V.C. Kyttaris & G.C. Tsokos. 2009. The role of IL-23/IL-17 axis in lupus nephritis. J. Immunol. 183: 3160-3169.
36. Kyttaris, V.C. et al. 2010. Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J. Immunol. 184: 4605-4609.
37. Xu, Z. et al. 2011. The NZM2410-derived lupus susceptibility locus Sle2c1 increases TH17 polarization and induces nephritis in Fas-deficient mice. Arthritis Rheum. 63: 764-774.
38. Rakhmanov, M. et al. 2009. Circulating CD21low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells. Proc. Natl. Acad. Sci. USA 106: 13451-13456.
39. Wehr, C. et al. 2004. A new CD21low B cell population in the peripheral blood of patients with SLE. Clin. Immunol. 113: 161-171.
40. -. J. Exp. Med. 208: 67-80.
41. + human B1 cell subpopulation stimulates T cells and is expanded in lupus. J. Exp. Med. 208: 2566-2569.
42. Mohan, C. et al. 1997. Genetic dissection of systemic lupus erythematosus pathogenesis-Sle2 on murine chromosome 4 leads to B cell hyperactivity. J. Immunol. 159: 454-465.
43. Montecino-Rodriguez, E., H. Leathers & K. Dorshkind. 2006. Identification of a B-1 B cell-specified progenitor. Nat. Immunol. 7: 293-301.
44. Ghosn, E.E. et al. 2011. Distinct progenitors for B-1 and B-2 cells are present in adult mouse spleen. Proc. Natl. Acad. Sci. USA 108: 2879-2884.
45. Xu, Z. et al. 2005. Genetic dissection of the murine lupus susceptibility locus Sle2: contributions to increased peritoneal B-1a cells and lupus nephritis map to different loci. J. Immunol. 175: 936-943.
46. Hayakawa, K. et al. 1983. The "Ly-1 B" cell subpopulation in normal immunodefective, and autoimmune mice. J. Exp. Med. 157: 202-218.
47. Xu, Z. et al. 2011. Cyclin-dependent kinase inhibitor Cdkn2c regulates B cell homeostasis and function in the NZM2410-derived murine lupus susceptibility locus Sle2c1. J. Immunol. 186: 6673-6682.
48. Potula, H.H. & L. Morel. 2012. Genetic variation at an YY-1 response site regulates the transcription of cyclin-dependent kinase inhibitor p18 INK4C transcript in lupus-prone mice. J. Immunol. 188: 4992-5002.
49. Morse, L. et al. 1997. Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18 INK4c and IL-6. Immunity 6: 47-56.
50. Schrantz, N. et al. 2000. The expression of p18INK4 and p27kip1 cyclin-dependent kinase inhibitors is regulated differently during human B cell differentiation. J. Immunol. 165: 4346-4352.
51. Tourigny, M.R. et al. 2002. CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. Immunity. 17: 179-189.
52. Leone, P.E. et al. 2008. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin. Cancer Res. 14: 6033-6041.
53. Wang, Y.Y. et al. 2010. RNA interference reveals a requirement for both p18 INK4c and p27 Kip1 in B lymphopoiesis. J. Mol. Cell Biol. 2: 209-216.
54. Huang, X. et al. 2004. Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. Proc. Natl. Acad. Sci. USA 101: 17789-17794.
55. Piatelli, M.J. et al. 2003. Cell cycle control mechanisms in B-1 and B-2 lymphoid subsets. Immunol. Res. 27: 31-51.
56. Solvason, N. et al. 2000. Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. Interntl. Immunol. 12: 631-638.
57. Tanguay, D.A. et al. 1999. Early induction of cyclin D2 expression in phorbol ester-responsive B-1 lymphocytes. J. Exp. Med. 189: 1685-1690.
58. Mataraza, J.M. et al. 2006. Disruption of cyclin D3 blocks proliferation of normal B-1a cells, but loss of cyclin D3 is compensated by cyclin D2 in cyclin D3-deficient mice. J. Immunol. 177: 787-795.
59. Potula, H.H. et al. 2012. Cyclin-dependent kinase inhibitor Cdkn2c deficiency promotes B1a cell expansion and autoimmunity in a mouse model of lupus. J. Immunol. 189: 2931-2940.
60. Kovalev, G.I. et al. 2001. An important role of CDK inhibitor p18(INK4c) in modulating antigen receptor-mediated T cell proliferation. J. Immunol. 167: 3285-3292.
61. + regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood. 106: 3068-3073.
62. Anderson, P. & E. Gonzalez-Rey. 2010. Vasoactive intestinal peptide induces cell cycle arrest and regulatory functions in human T cells at multiple levels. Mol. Cell. Biol. 30: 2537-2551.
63. Kim, K. et al. 2009. A regulatory SNP at position -899 in CDKN1A is associated with systemic lupus erythematosus and lupus nephritis. Genes Immun. 10: 482-486.
64. Kong, E.K. et al. 2007. p21 gene polymorphisms in systemic lupus erythematosus. Rheumatology (Oxford). 46: 220-226.
65. Yang, W. et al. 2013. Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians. Amer. J. Hum. Genet. 92: 41-51.
66. Tang, H. et al. 2009. Abnormal activation of the Akt-GSK3β signaling pathway in peripheral blood T cells from patients with systemic lupus erythematosus. Cell Cycle. 8: 2789-2793.
67. Arias, C.F. et al. 2007. p21CIP1/WAF1 controls proliferation of activated/memory T cells and affects homeostasis and memory T cell responses. J. Immunol. 178: 2296-2306.
68. Lawson, B.R. et al. 2004. Deficiency of the cyclin kinase inhibitor p21(WAF-1/CIP-1) promotes apoptosis of activated/memory T cells and inhibits spontaneous systemic autoimmunity. J. Exp. Med. 199: 547-557.
69. Katagiri, K. et al. 2011. Deficiency of Rap1-binding protein RAPL causes lymphoproliferative disorders through mislocalization of p27kip1. Immunity. 34: 24-38.
70. Cohen, P.L. & R.A. Eisenberg. 1992. The Lpr and Gld genes in systemic autoimmunity-life and death in the Fas lane. Immunol. Today 13: 427-428.
71. Xu, Z., B.P. Croker & L. Morel. 2013. The combination of two Sle2 lupus-susceptibility loci and Cdkn2c deficiency leads to T-cell-mediated pathology in B6.Fas mice. Genes Immun. 14: 373-379.
72. Reap, E.A. et al. 1993. Conventional B cells, not B-1 cells, are responsible for producing autoantibodies in lpr mice. J. Exp. Med. 177: 69-78.